Clinical trial

A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active…

NCT00404885 · Lux Biosciences, Inc., Industry · Completed

Key facts

NCT number NCT00404885
Title A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
Official title A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Anterior Uveitis
Acronym LUMINATE
Lead sponsor Lux Biosciences, Inc., Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Uveitis, Anterior, Panuveitis
Intervention type Drug
Interventions Placebo, LX211
Enrollment 108
Start date Jan 1, 2007
Primary completion Nov 1, 2008
Completion May 1, 2009
First posted Nov 29, 2006
Last update posted Jun 22, 2012
Countries Austria, Canada, France, Germany, India, United Kingdom, United States

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies